Search

Compugen Ltd

Abierto

2.52 1.61

Resumen

Variación precio

24h

Actual

Mínimo

2.41

Máximo

2.5300000000000002

Métricas clave

By Trading Economics

Ingresos

663K

-7M

Ventas

426K

2.6M

P/B

Media del Sector

6.816

56.597

BPA

-0.07

Margen de beneficios

-269.254

Empleados

75

EBITDA

665K

-7M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+102.43% upside

Dividendos

By Acuity

Próximas Ganancias

9 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

20M

245M

Apertura anterior

0.91

Cierre anterior

2.52

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 sept 2026, 23:51 UTC

Brazil's Business Confidence Index (ICEI) for September 2026 set to release on September 14, with cautious optimism amid persistent pessimism and geopolitical challenges.

13 sept 2026, 23:41 UTC

GBP/AUD shows notable strength in after-market trading, reaching a cumulative return peak of 0.17% since Friday's close, with no specific news identified.

13 sept 2026, 23:41 UTC

Correlated Moves

EUR/AUD is higher in after-market trading, diverging from the lower Nasdaq 100 Index amid heightened Fed interest rate hike expectations following a strong consumer price index report.

13 sept 2026, 23:31 UTC

China's House Price Index YoY release on September 15, 2026, is anticipated to reveal ongoing weakness in the housing sector amid cautious optimism from recent policy measures.

13 sept 2026, 23:31 UTC

U.S. Building Permits Forecasted at 1.41 Million for August Amid Stable Market Sentiment Ahead of September Release

13 sept 2026, 23:31 UTC

Upcoming U.S. Housing Starts Data Release on September 17 Expected to Influence Economic Outlook Amidst Market Fluctuations.

13 sept 2026, 23:31 UTC

U.S. Housing Starts Expected to Recover Slightly to 1.32 Million Units Amid Ongoing Concerns Over High Mortgage Rates and Recent Declines

13 sept 2026, 23:31 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Positive Sentiment and Anticipated Growth, Forecasted at 30.0

13 sept 2026, 23:31 UTC

U.S. Building Permits Data Set for Release on September 17, 2026, Amid Cautious Optimism in Housing Market Sentiment

13 sept 2026, 23:31 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Cautious Optimism on Consumer Spending

13 sept 2026, 23:31 UTC

Retail Sales MoM report for August 2026 set to release on September 16, with a forecasted increase of 0.9% amid cautious consumer spending sentiment following July's unexpected decline.

13 sept 2026, 23:31 UTC

U.S. Import Prices MoM data for August 2026 set to release on September 16, with a modest increase of 0.2% expected amid inflation concerns and potential Fed interest rate adjustments.

13 sept 2026, 23:31 UTC

U.S. Export Prices MoM Release on September 16 Expected to Impact Monetary Policy Amidst Recent Price Decline and Mixed Market Sentiment

13 sept 2026, 23:21 UTC

Macro News
News

Bitcoin is lower as U.S.-China tensions rise and crude oil prices fall. Regulatory optimism around the Bitcoin and Crypto Clarity Act fails to boost sentiment.

13 sept 2026, 23:11 UTC

EUR/NZD is trading lower during after-market hours, settling at -0.11%. The currency pair remains above its 20-day moving average.

13 sept 2026, 23:01 UTC

EUR/JPY trades higher in after-market hours, recovering from earlier lows amid expectations for a Federal Reserve interest rate hike on September 16.

13 sept 2026, 23:01 UTC

Correlated Moves

The AUD/USD is lower during after-market hours, reflecting declines in the Nasdaq 100 Index and influenced by recent consumer price index data.

13 sept 2026, 23:01 UTC

Macro News
Correlated Moves

Geopolitical tensions with China and domestic electricity concerns contribute to a decline in the Dow Jones Index, which has reached a session low below its 20-day moving average.

13 sept 2026, 23:01 UTC

Macro News
Correlated Moves

U.S.-China tensions rise over arms deals with Taiwan, impacting market sentiment. The S&P 500 Index is trading lower today, reflecting broader market weakness.

13 sept 2026, 23:01 UTC

Macro News

Geopolitical tensions are driving WTI prices higher as concerns about U.S.-China relations and Iranian pressures on Saudi Arabia impact global oil markets.

13 sept 2026, 23:01 UTC

Correlated Moves

The Russell 2000 Index is lower today, continuing a downward trend amid broader market sentiment influenced by rising core CPI data and Fed rate hike expectations.

13 sept 2026, 23:01 UTC

Correlated Moves

Platinum is trading lower, influenced by a decline in silver prices amid rising consumer inflation and expectations for a Federal Reserve interest rate hike.

13 sept 2026, 23:01 UTC

EUR/SEK is trading lower during after-market hours, reflecting a slight decline since Friday's close. The asset remains near its one-month range high.

13 sept 2026, 23:01 UTC

Correlated Moves

Silver prices are lower, influenced by gold's decline and inflation data. The asset remains below its 20-day moving average amid market pressures.

13 sept 2026, 23:01 UTC

The Nasdaq 100 Index is lower amid ongoing market weakness, following a consumer price index report that exceeded expectations and heightened rate hike speculation.

13 sept 2026, 23:01 UTC

Natural Gas is trading higher, continuing gains from Friday's close. Prices reached their highest point during the session, with no specific news identified.

13 sept 2026, 23:01 UTC

EUR/CZK is trading lower in after-market hours, reflecting a modest decline since Friday's close amid solidified market expectations for a Federal Reserve interest rate hike.

13 sept 2026, 23:01 UTC

Macro News
Correlated Moves

Gold prices are lower as market expectations grow for a Federal Reserve interest rate hike. Goldman Sachs anticipates a 25 basis-point increase at the FOMC meeting.

13 sept 2026, 23:01 UTC

Ethereum is trading lower, continuing a downward trend since Saturday's close. The asset reached a session low earlier today.

13 sept 2026, 22:51 UTC

Canada's Housing Starts Data Release on September 16 Expected to Show Continued Weakness Amid Economic Pressures

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

102.43% repunte

Estimación a 12 Meses

Media 5 USD  102.43%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat